Overview: Kisqali 200 mg (Ribociclib)
Kisqali 200 mg, containing the active ingredient Ribociclib, is an advanced targeted therapy developed by Novartis. It is classified as a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, scientifically formulated to inhibit the progression of cancer cells in specific types of breast cancer.
Mechanism and Clinical Utility
Kisqali works by inhibiting the CDK4/6 proteins, which play a crucial role in cell division and proliferation. By blocking these pathways, Kisqali helps to slow down the growth and division of cancer cells. This medication is a cornerstone in modern oncology treatment plans, particularly for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer.
Key Therapeutic Benefits
- Targeted CDK4/6 Inhibition: Highly specific action that targets the cell cycle machinery to effectively control tumor growth.
- Advanced Oncology Support: Designed to be used in conjunction with endocrine therapy, offering a comprehensive approach to managing metastatic breast cancer.
- Clinical Reliability: Developed by Novartis, a global leader in oncology research, ensuring high standards of therapeutic efficacy.
- Precise Dosing: Provided as 200 mg film-coated tablets, allowing for flexible and accurate titration according to oncologist recommendations.
Product Details and Usage
Kisqali 200 mg is provided in a 63-tablet supply per unit. This presentation is designed to support the dosing schedules required for effective long-term breast cancer management, ensuring patients have reliable access to their prescribed treatment.
Safety and Storage Guidelines
Administration: Must be taken strictly as prescribed by your oncologist. Adjustments to therapy or dosing must be performed only by authorized medical professionals.
Storage: Store the tablets in their original packaging in a cool, dry place. Keep out of reach of children and ensure the storage environment remains within standard temperature limits.
Healthcare Collaboration: Maintain consistent communication with your oncology care team and the specialists at El-Masry Pharmacy to ensure optimal treatment outcomes and to address any clinical concerns promptly.
Disclaimer: Kisqali is a specialized, prescription-only oncology medication. Ensure you hold a valid prescription and consult with your healthcare provider before beginning any treatment plan.
You can add a rating once you purchase the product through the My Orders page
